New hope for slowing advanced prostate cancer
NCT ID NCT04633252
Summary
This study is testing whether adding an experimental immunotherapy drug called PDS01ADC to standard chemotherapy (docetaxel) is safe and can help men whose prostate cancer has spread. It is for men with two types of advanced prostate cancer: one that still responds to hormone therapy and one that has stopped responding. The main goals are to find a safe dose and see if the combination can better control the cancer by lowering PSA levels and delaying its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF PROSTATE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.